Shares of Duopharma Biotech Bhd (KL:DPHARMA) have climbed to their highest in about three years after the group's latest contract wins for the supply of insulin products and injections with the Ministry of Health (MOH).

KUALA LUMPUR (Feb 16): Duopharma Biotech Bhd (KL:DPHARMA) has received two letters of award worth a sum value of RM116.72 million to supply insulin products and insulin injections to the Ministry of Health (MOH) and its facilities.

KUALA LUMPUR: Bursa Malaysia’s benchmark index trended upward to end the morning session higher as investors regained buying interest in heavyweights, taking the cue from upbeat regional markets.

KUALA LUMPUR: Bursa Malaysia's benchmark index trended upward to end the morning session higher as investors regained buying interest in heavyweights, taking the cue from upbeat regional markets.

KUALA LUMPUR: Bursa Malaysia ended the morning session lower, tracking the weakness in regional markets amid cautious global sentiment.

KUALA LUMPUR: Bursa Malaysia ended the morning session lower, tracking the weakness in regional markets amid cautious global sentiment.

（吉隆坡1日讯）随着外围风险消退，大马股市近期稳步走高，综指也跨越1620点关口，分析员认为，马股在2025年末季的前景是更宽阔、更安全的跑道。惟马股估值与同侪相比，已经不算低，因此建议投资者放眼大型股以外的选择。肯纳格研究分析员说，马股目前以低于10年本益比平均水平的0.5个标准差交易，尽管美国关税政策更加明朗，区域股市大多数反弹，富时吉隆坡综指则几乎持平，而且若用更广泛的股票指标，如富时100指数，今年迄今，大马股市表现仍下跌4.5%。根据彭博社7月至9月的数据，东盟的外资持续净流出，大...

KUALA LUMPUR: The FBM KLCI opened nearly flat on Friday before slipping into the red, despite Wall Street's record-high closes overnight after the US Federal Reserve cut interest rates by 25 basis points.

The recently concluded second quarter of financial year 2025 (2Q25) results reporting season saw slight deterioration in earnings delivery against its expectations, with private hospitals, health supplement and pharmaceutical players reporting a mixed set of results, according to Kenanga Research.

（吉隆坡26日讯）销售下跌和净外汇损失，拖累康大工业（KOTRA,0002,主板医疗保健组）截至2025年6月30日末季净利减少21.23%，跌至983万5000令吉；全年净利也跌4.76%，报4247万5000令吉。第四季营业额下滑12.36%，报5242万5000令吉；全年营业额增1.87%，挂2亿3078万4000令吉，归咎于本地和出口市场的保健产品销售减少。配合发布业绩，董事部派发每股13仙股息，将在10月13日除权、10月14日享有和10月24日派给股东。展望未来，公司董事部将继...

Now in its fifth edition, The Edge Malaysia Centurion Club Corporate Awards has established itself as a key benchmark for Malaysia’s mid-tier listed companies, standing alongside its sister awards, The Edge Billion Ringgit Club (BRC), which recognises top-performing large-cap companies.

KUALA LUMPUR: The FBM KLCI ended slightly higher on Monday as renewed U.S. tariff threats kept investors cautious, driving demand for safe-haven assets like gold, which touched a three-week high.

SEOUL: South Korea’s exports to the Association of Southeast Asian Nations (Asean) countries are on the rise, helping offset recent drops in shipments to the United States (US) and China amid a global trade war sparked partly by the US’ evolving tariff policies, data showed Sunday.

The earnings momentum for private healthcare, health supplements and pharmaceuticals providers will continue into the second half of this year (2H25) as demand for such services and goods keep rising.

（吉隆坡20日讯）递延税务资产回拨，带动康大工业（KOTRA,0002,主板医疗保健组）截至2025年3月31日第三季净利上升74.79%，增至1194万5000令吉；首9个月净利微升1.65%，报3264万令吉。该公司第三季营业额上涨4.40%至5833万6000令吉；首9个月营业额增加6.97%，升至1亿7835万9000令吉。根据康大工业的业绩报告，康大工业第三季营业额上涨，主要由本地国内和出口市场的医疗产品销售增加带动。另外，国内市场的补充产品销售增加，抵销出口市场的需求减少的冲击。...

An executive order signed by US President Donald Trump is not seen to have much impact on the Malaysian pharmaceutical sector, though there could be increased scrutiny on drug costs and the local supply chain.

在关税贸易战越发激烈及地缘政治风险影响之下，表面上看似一片繁荣的半导体产业升级，实则面临诸多挑战与未知数。

A focus on growing revenue has paid off for Duopharma Biotech Bhd (KL:DPHARMA), which reported its highest annual revenue on record last year. After rising costs and softer demand sent its net profit down 25% in 2023, the country’s largest generic drug manufacturer by market share is ba...

（吉隆坡、首尔27日讯）任何具有策略意义的外国投资项目，都有望在柔新经济特区（JS-SEZ）中获得“量身打造”的奖励措施...

疾病增加以及消费者意识增强，康大工业（KOTRA，0002，主板保健股）的营养保健品有望能从中受益。